Archer Materials Advances 12CQ Quantum Chip and A1 Biochip
Archer Materials Announces Q1 Medical Diagnostics and Quantum Computing Progress.
Archer Materials Limited, a quantum and advanced semiconductor solutions firm, reported Q1 CY25 technological and commercial achievements. An Archer spokeswoman called the quarter a period of concentrated and exceptionally strong technical execution for the company's flagship 12CQ quantum computing chip and A1 Biochip.
Archer Materials develops solutions for global concerns that conventional technologies cannot answer to advance computers, sensing, and healthcare. Q1 2025 reveals that the company is getting closer to creating world-changing products.
12CQ Chip Improves Qubit Architecture and Control The 12CQ project aims to produce a stable, room-temperature qubit processor for real-world quantum computing. Q1 CY25 operations focused on improving quantum operation control and readout technologies.
Refine Qubit Control Archer developed new device topologies that allow electron manipulation, advancing technology. This architectural breakthrough underpins “gating,” which controls the qubit's quantum state. The underlying technology was refined to achieve accurate spin state control for next-generation qubits.
Two proof-of-concept superconducting circuit circuits were built for quantum processor data out-take during readout activity. Single-electron transistors and electron spin state readout, two key Qubit Roadmap components, are also being built.
Material Science and Manufacturing Commercial scale requires repeatable, reliable materials. In Q1, the company enhanced carbon nanosphere quantum spin coherence durations. While improving its newly manufactured carbon films, Archer increased their reproducibility from sample to sample, which is crucial for large-scale production. A breakthrough in quantum carbon sheets for qubit realisation is an example.
By mid-2026, the company will exhibit a complete qubit with readout and single spin control. Its long-term cooperation with Queen Mary University of London aids Archer's qubit demonstration. Controlling one or a few qubits is a major technological milestone for Archer and quantum computing. Archer protected its 12CQ technology with US, Chinese, and South Korean patents.
Biochip Innovation: A1 Nears Human Blood Testing Archer's A1 Biochip, a graphene sensor for fast medical diagnosis, met precision and manufacturing milestones in the quarter. The Biochip's main use is creating an at-home blood potassium sensor for CKD management. Identifying potentially fatal potassium imbalances with this device could help millions of chronic kidney disease (CKD) patients worldwide.
Accuracy, Diagnostics In order to allow human blood testing, the Biochip team reported improved accuracy. Potassium-sensing precision has improved enough to build a reliable diagnostic tool. Rapid blood testing for chronic renal disease is one of the Biochip's advanced medical diagnostics.
Commercial Readiness and Miniaturisation Archer prioritised foundry readiness and manufacturing cost reduction to hasten product commercialisation. First manufacture of the complex graphene field effect transistor (gFET) Biochip design on a six-inch wafer was impressive. By reducing its gFET design by 97%, the business reduced manufacturing costs and prepared the technology for home testing equipment.
Strategic Partnerships and IP The announcement of a partnership with Hylid Diagnostics in late Q1 accelerated productisation. This relationship will emphasise Biochip product integration and treatment pathways. The company is aggressively seeking strategic collaborations with medical diagnostics firms to ensure productisation and regulatory planning.
This quarter, the business won a Key Biochip Patent, bolstering its distinctive technology. Archer plans to begin clinical trials in 2026 and have a blood potassium sensor lab demonstrator by 2025.
Corporate momentum and global reach The first quarter of 2025 gave Archer momentum for expansion. Dr. Simon Ruffell became CEO in March, bolstering the leadership team. Dr. Ruffell will lead the final push for a fully functional qubit demonstration.
Archer's membership in the IBM quantum network and the World Economic Forum's Centre for the Fourth Industrial Revolution demonstrate its strategic focus on cooperation and international networks. The company, based in Adelaide and Sydney, pioneered quantum technologies that would transform computing, sensing, and healthcare.